FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1569-1572 October 16, 2003 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Zuger, A. Related Article by Scardino, P. T. Related Article by Thompson, I. M. PubMed Citation

To the Editor: One perplexing finding of the Prostate Cancer Prevention Trial (July 17 issue)¹ is that more high-grade tumors were detected in the finasteride group than in the placebo group. It is hard to put this finding into perspective because of the limited published data on the effects of finasteride on prostate cancer. Yang et al. have reported on a series of needle biopsies of the prostate in men treated with finasteride.² No significant differences were seen between the treatment group and the control group with respect to multiple variables, including the Gleason grade. However, their study was nonrandomized . . . [Full Text of this Article]

This article has been cited by other articles:

• Thompson, I. M., Chi, C., Ankerst, D. P., Goodman, P. J., Tangen, C. M., Lippman, S. M., Lucia, M. S., Parnes, H. L., Coltman, C. A. Jr. (2006). Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer.. JNCI J Natl Cancer Inst 98: 1128-1133 [Abstract] [Full Text]  
• Rosner, W. (2004). Proscar and Propecia--A Therapeutic Perspective. J. Clin. Endocrinol. Metab. 89: 3096-3098 [Full Text]